Mustafa ÜNLÜ, Aynur OĞUZ, Nurten TÜRKÖZKAN, Alev HASANOĞLU, Ceyda KARADENİZ, Aysu Duyan ÇAMURDAN, Mahmut Orhun ÇAMURDAN

Bone mineral densty after treatment of non-Hodgkın's lymphoma in childhood

Bu çalışma non-Hodgkin lenfomalı çocuklarda kullanılan sitotoksik ilaçların kemik mineral dansitesi üzerindeki yan etkilerini araştırmak amacıyla planlandı. Gereç ve Yöntemler: Kesitsel bir çalışma yürütüldü. Hasta grubu 31 (6’sı kız, 25’i erkek) tedavisi tamamlanmış non-Hodgkin lenfomalı olgudan oluşuyordu. Kontrol grubu 30 (11’i kız, 19’u erkek) sağlıklı çocuktan oluşturuldu. Her iki grubun da vertebra ve femur kemik mineral dansite ölçümleri kemik döngüsünü gösteren biyokimyasal parametreleri incelendi. Bulgular: Hasta ve kontrol grubundaki olguların yaşları, cinsiyetleri, vücut ağırlıkları, boyları, puberte evreleri, laboratuvar parametreleri istatistiksel olarak benzerdi. Hasta grubunun ortalama kemik mineral dansitesi (g/m2) kontrol grubundan düşük olmasına karşın fark istatistiksel olarak anlamlı değildi (sırasıyla, BMD-V: 0,574±0,188 gr/cm2, BMD-F: 0,658±0,191 gr/cm2 vs BMD-V: 0,644±0,158 gr/cm2, BMD-F: 0,718±0,128 gr/cm2 , p>0.05). Sonuç: Bu çalışmada hasta ve kontrol grupları arasında istatistiksel anlamlı fark bulunmamasına karşın hasta grubundaki düşük kemik minarel dansitesi ölçümü non-Hodgkin lenfoma’lı çocukların kemik yoğunluğunun sitotoksik tedaviden etkilenebileceğini düşündürmektedir.

Çocukluk çağı non-Hodgkin lenfoma tedavisi sonrası kemik mineral dansitesi

To investigate the side effects of cytotoxic drugs on bone mineral density in children with non-Hodgkin’s lymphoma. Materials and Methods: A cross-sectional study was conducted. The patient group was composed of 31 (6 girls and 25 boys) non-Hodgkin’s lymphoma patients who had completed their therapy. The control group was composed of 30 (11 girls and 19 boys) healthy children. The bone mineral density of the vertebrae (BMD-V) and femur (BMD-F) and biochemical parameters of bone turnover were studied in both groups. Results: The patient and control groups were statistically similar in terms of age, sex, body weight, height, pubertal status, and laboratory parameters (p >0.05). Mean bone mineral density values (g/m2) in the patient group were lower than those in the control group, but not significantly so (respectively, BMD-V: 0.574±0.188 g/cm2, BMD-F: 0.658±0.191 g/cm2 vs. BMD-V: 0.644±0.158 g/cm2, BMD-F: 0.718±0.128 g/cm2, p>0.05). Conclusion: Although there was no significant difference between bone mineral density measurements of the patients and controls, the lower levels of bone density in patients could indicate that the bone mineral density of patients with non-Hodgkin lymphoma was affected by cytotoxic therapy. This should be taken into consideration in the follow-up of such children.

PDF

___

1. Vassilopoulou-Sellin R, Brosnan P, Delpassand A, et al. Osteopenia in young adult survivors of childhood cancer. Med Pediatr Oncol. 1999; 32: 272-278.
2. Neglia JP, Nesbit ME. Care and treatment of long term survivors of childhood cancer. Cancer 1993; 71: 3386-3391.
3. Bleyer WA. The impact of childhood cancer on United States and the world. CA Cancer J Clin 1990; 40: 355.
4. Gilsanz V, Carlson ME, Roe TF, et al. Osteoporosis after cranial irradiation for acute lymphoblastic leukemia. J Pediatr 1990; 117(2 Pt 1): 238-244.
5. Murray RD, Brennan BM, Rahim A, et al. Survivors of childhood cancer: long-term endocrine and metabolic problems dwarf the growth disturbance. Acta Paediatr 1999; 88(433): 5-12.
6. Van Leeuwen BL, Kamps WA, Jansen HW, et al. The effect of chemotherapy on the growing skeleton. Cancer Treat Rev 2000; 26: 363-376.
7. Kaste SC, Chesney RW, Hudson MM, et al. Bone mineral status during and after therapy of childhood cancer: an increasing population with multiple risk factors for impaired bone health. J Bone Miner Res 1999; 14: 2010-2014.
8. Arikoski P, Kroger H, Riikonen P, et al. Disturbance in bone turnover in children with a malignancy at completion of chemotherapy. Med Pediatr Oncol. 1999; 33: 455-461.
9. Fassler ALC, Bonjour JP. Osteoporosis as a pediatric problem. Ped Clin North Am 1995; 42: 811-824.
10. Matkovic V, Fontana D, Tominac C, et al. Factors that influence peak bone mass formation: a study of calcium balance and the inheritance of bone mass in adolescent females Am J Clin Nutr 1990; 52: 878- 888.
11. Sambrook PN, Kelly PJ, Morrison NA, et al. Genetics of osteoporosis. Br J Rheumat 1994; 33: 1007-1011.
12. Nysom K, Holm K, Michaelsen KF, et al. Bone mass after treatment for acute lymphoblastic leukemia in childhood. J Clin Oncol 1998; 16: 3752-3760.
13. Kaste SC, Jones-Wallace D, Rose SR, et al. Bone mineral decrements in survivors of childhood acute lymphoblastic leukemia: frequency of occurrence and risk factors for their development. Leukemia 2001; 15: 728-734.
14. Cooper C, Aihie A. Osteoporosis: recent advances in pathogenesis and treatment. QJM 1994; 67: 203-209.
15. Del Rio L, Carrascosa A, Pons F, et al. Bone mineral density of the lumbar spine in white Mediterranean Spanish children and adolescents: changes related to age, sex, and puberty Pediatr Res 1994; 35: 362-366.
16. Nieves JW, Golden AL, Siris E, et al. Teenage and current calcium intake are related to bone mineral density of the hip and forearm in women aged 30-39 years. Am J Epidemiol 1995; 141: 342-351.
17. Riggs BL, Melton III LJ. Involutional osteoporosis. N Engl J Med 1986; 314:1676-1686.
18. Sentipal JM, Wardlaw GM, Mahan J, et al. Influence of calcium intake and growth indexes on vertebral bone mineral density in young females. Am J Clin Nutr 1991; 54: 425-428.
19. Shad A, Magrath IT. Malignant non-Hodgkin’s lymphomas in children. In: Pizzo PA. Poplack DG eds. Principles and Practice of Pediatric Oncology. 3rd ed. Philadelphia: Lippincott Raven, 1997, P: 545-587.
20. Marshall WA, Tanner JM. Variations in the pattern of pubertal changes in girls. Arch Dis Child 1969; 44: 291-303.
21. Marshall WA, Tanner JM. Variations in the pattern of pubertal changes in boys. Arch Dis Child 1970; 45: 13-23.
22. Endres DB, Rude RK. Mineral and bone metabolism. In: Burtis CA, Ashwood ER, eds. Tietz Fundamentals of Clinical Chemistry 4th ed. Philadelphia: W.B. Saunders Company, 1996, P: 685-701.
23. Goldsmith DI, Novello AC. Clinical and laboratory evaluation of renal function. In: Edelman CH ed. Pediatric Kidney Disease 2nd ed. USA: Little, Brown and Company, 1992, P: 461-472.
24. Kröger H, Kotaniemi A, Vainio P, et al. Bone densitometry of the spine and femur in children by dual-energy X-ray absorptiometry. Bone Miner 1992; 17: 75-85.
25. Barr RD, Atkinson SA. Bone mineral density in survivors of cancer in childhood. J Pediatr Hematol Oncol 1999; 21: 249.
26. Nussey SS, Hyer SL, Brada M, et al. Bone mineralization after treatment of growth hormone deficiency in survivors of childhood malignancy. Acta Paediatr 1994; 399: 9-14.
27. Rohn RD, Werner EJ, Byrd RL. Osteoporosis as the presenting sign of leukemic relapse in an adolescent: case report and literature review. J Adol Health 1992; 13: 306-310.
28. Vassilopoulou-Sellin R, Ramirez I. Severe osteopenia and vertebral compression fractures after complete remission in an adolescent with acute leukemia. Am J Hematol 1992; 39: 142-143.
29. Kadan-Lottick N, Marshall JA, Baron AE, et al. Normal bone mineral density after treatment for childhood acute lymphoblastic leukemia diagnosed between 1991 and 1998. J Pediatr 2001; 138: 898-904.
30. Warner JT, Evans WD, Webb DK, et al. Relative osteopenia after treatment for acute lymphoblastic leukemia. Pediatr Res 1999; 45(4 Pt 1): 544-551.
31. Nysom K, Molgaard C, Holm K, et al. Bone mass and body composition after cessation of therapy for childhood cancer. Int J Cancer 1998; 11: 40-43.
32. Atkinson SA, Halton JM, Bradley C, et al. Bone mineral abnormalities in childhood acut lymphoblastic leukemia: influence of disease, drugs and nutrition. Int J Cancer 1998;
33. Van der Sluis IM, van den Heuvel-Eibrink MM, Hahlen K, et al. Bone mineral density, body composition and height in long-term survivors of acute lymphoblastic leukemia in childhood. Med Pediatr Oncol 2000; 35: 415-420.
34. Nysom K, Holm K, Michaelsen KF, et al. Bone mass after allogeneic BMT for childhood leukaemia or lymphoma. Bone Marrow Transplant 2000; 25: 191-196.
35. Hoorweg-Nijman JJ, Kardos G, Roos JC, et al. Bone mineral density and markers of bone turnover in young adult survivors of childhood lymphoblastic leukemia. Clin Endocrinol (Oxf) 1999; 50: 237-244.
36. Brennan BM, Rahim A, Adams JA, et al. Reduced bone mineral density in young adults following cure of acute lymphoblastic leukaemia in childhood. Br J Cancer 1999; 79(11-12): 1859-1863.
37. Atkinson SA, Fraher L, Gundberg CM, et al. Mineral homeostasis and bone mass in children treated for acute lymphoblastic leukemia. J Pediatr 1989; 114: 793-800.
38. O’Regan S, Melhorn DK, Newman AJ. Methotrexate induced bone pain in childhood leukemia. AJDC 1973; 126: 489-494.
39. Ragab AM, Frech RS, Vietti RJ. Osteoporotic fractures secondary to methotrexate therapy of acute leukemia in remission. Cancer 1970; 25: 580-585.
40. Hahn TJ, Boisseav VC, Avioli LV. Effects of chronic corticosteroid administration on diaphyseal and metaphyseal bone mass. J Clin Endocrinol Metab 1974; 39: 274-282.
41. Hahn TJ, Halstead LR, Teitelbaum SL, et al. Altered mineral metabolism in glucocorticoid induced osteopenia. Clin Invest 1979; 64: 655-665.
42. Zonneveld IM, Bakker WK, Dijkstra PF, et al. Methotrexate osteopathy in long term, low-dose methotrexate treatment for psoriasis and rheumatoid arthritis. Arch Dermatol 1996; 132: 184-187.
43. Holmes SJ, Whitehouse RW, Clark ST, et al. Reduced bone mineral density in men following chemotherapy for Hodgkin’ s disease. Br J Cancer 1994; 70: 371-375.
44. Rickers H, Deding A, Christiansen C, et al. Mineral loss in cortical and trabecular bone density high-dose prednisone treatment. Calcif Tissue Int 1984; 36: 269-273.
45. De Schepper J, Hachimi-Idrissi S, Louis O, et al. Bone metabolism and mineralisation after cytotoxic chemotherapy including ifosfamide. 11: 35-39.Arch Dis Child 1994; 71: 346-348.